Pharma executives are breathing a sigh of relief this week thanks to news that Sen. Charles Grassley (R-IA) is stepping down from his role as head of the Senate Finance Committee. He'll move to the Senate Judiciary Committee instead. Hill gossip says with Grassley's transition, pharma may see the end of a steady stream of demanding letters from Grassley, who's been a real gadfly on the subject of drugmakers' relationships with doctors and academic medical centers. FiercePharma